A Vacation Break

Things will get interesting with the upcoming pre-announcements and Q2 earnings reports. There's been some good news recently with the big cap biotechs. Genentech received FDA approval for Lucentis, which is used to treat age related blindness. Celgene received approval of Revlimid for the treatment of multiple myeloma. There was an interesting write in the Wall Street Journal in which an analyst reported that Celgene generates a gross margin of ~ 97% from this drug. The company denies this, but if it's true, wow...

Anyways... I'll be away on vacation for the next two weeks. Enjoy the July 4th festivities!